GlassScriptPhysician profile
Angela Lynn Patterson
NPI 1528729993
$4,344.52
in general payments reported to CMS, 2019-2025
25 companies · $939 in 2025
The $939 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,514 · 2023: $1,073 · 2024: $818 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.46 | 2022-2025 | |
| Pfizer INC. | $617.10 | 2022-2025 | |
| Lilly USA, LLC | $472.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $436.29 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $393.35 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $316.73 | 2022-2025 | |
| Exact Sciences Corporation | $272.65 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $184.47 | 2022-2023 | Hetlioz |
| Amgen INC. | $146.00 | 2022-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $142.82 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $135.83 | 2024-2025 | Veozah |
| Abbott Laboratories | $114.70 | 2022-2023 | Freestyle Libre 3 |
| Smith+Nephew, INC. | $98.60 | 2023 | Pico, Renasys Touch |
| Sanofi-Aventis U.S. LLC | $83.47 | 2022 | |
| Merck Sharp & Dohme LLC | $39.80 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2022-2024 | Jardiance |
| Mylan Specialty L.P. | $26.87 | 2022 | |
| Insmed, INC. | $26.19 | 2025 | Arikayce |
| Biohaven Pharmaceutical Holding Company LTD. | $25.77 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.99 | 2022 | |
| Boston Scientific Corporation | $21.86 | 2025 | Wavewriter Alpha Prime 16 |
| Antares Pharma, INC. | $20.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.51 | 2024 | Xifaxan |
| Tris Pharma INC | $19.46 | 2025 | Dyanavel Xr |
| Horizon Therapeutics Plc | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.